The latest diatribes here are somewhat wrong and misleading. I too am a frustrated and disappointed holder in this baby. Its been an arduous stock, but one I still believe is a baby SRX. The pancreatic market is huge and this offers the best form of adjunct treatment.
Sure the Company has been quiet, but enough was said in the last announcement. I think we'll see a bevy of announcements beginning soon in this one, with patient dosing beginning, more hospitals signed up and ethics approvals too.
Its extremely cheap down here and the big holders seem to be maintaining, with only the totally frustrated giving up.
The company will likely have dosed all 20 patients by the end of June and the read-out is only 1 page per patient and after 8 weeks. That reads a lovely spring for holders. For SP predictions, I reckon we'll see double figures again next month and moving steadily towards old highs as the read out occurs. Any CR will be well after read-outs when the company will have ample support.
My 2c and whilst biased seems more than realistic!
OSL Price at posting:
7.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)